[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-neoplasm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100410281","early-prediction-of-oral-cancer-by-s100a7-immunohistochemistry-signature-based-assessment-100410281",false,"NCT04622462","Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment","A Multi-Centre Prospective Community-Based Observational Study on Prediction of Malignant Progression of Clinically Suspicious Oral Lesions With STRATICYTE","Inclusion Criteria:\n\n* Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia\u002Foral squamous cell carcinoma\n\nExclusion Criteria:\n\n* Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy","ALL","15 Years","90 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.",[25],"Oral Neoplasm",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58],"Leukoplakia","Erythroplakia","Erythroleukoplakia","Lesion","Oral Epithelial Dysplasia","S100A7 Biomarker","S100A7 Immunohistochemistry Signature-based","Early Diagnosis","STRATICYTE","Oral Neoplasia","Oral Epithelial Atypia","Hyperplasia","Hyperkeratosis","Oral Squamous Cell Carcinoma","Oral Cancer","Potentially Premalignant Oral Epithelial Lesion","OPMD","Mild Dysplasia","Moderate Dysplasia","Severe Dysplasia","Low-grade Dysplasia","High-grade Dysplasia","Personalized Medicine","Predictive Assay","Whole Slide Imaging","Computational Pathology","Digital Pathology","Artificial Intelligence","Machine Learning","OPML","Oral Potentially Malignant Disorder","Oral Potentially Malignant Lesion","RECRUITING","2024-11-05",{"date":62,"type":63},"2024-11-07","ACTUAL",{"date":65,"type":63},"2015-03-12",{"date":67,"type":21},"2026-12-31",{"name":69,"class":70},"Proteocyte Diagnostics Inc.","INDUSTRY",3,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100567034","arabic-pro-measures-for-head-and-neck-cancer-radiotherapy-100567034","NCT06662929","Arabic PRO Measures for Head and Neck Cancer Radiotherapy.","Arabic Patient-reported Outcome Measures During Radiotherapy for Head and Neck Cancer: a Validation Study","PROMs","Inclusion Criteria:\n\n* Adults aged 18 or above and who is planned for receiving and who is currently receiving and who had already received radiotherapy for the HNC at King Saud University Medical City.\n\nExclusion Criteria:\n\n* Individuals who are less than 18 years, presence of debilitating disease (e.g. heart failure) or who lack the capacity to read, understand and sign the informed consent and those.","18 Years",{"count":82,"type":21},125,"2 Weeks","The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools. PROM tools are not validated cross-culturally in Arabic-speaking patient populations, which limits their use in our clinical setting. Validation of these PROM tools will allow clinicians to identify the concerns related to our patient population and measure the outcome of our interventions. Main objectives are:\n\n* To further validate (cross-culture) the PROM instruments related to head and neck cancer (HNC) in Arabic patients.\n* To investigate the prevalence and severity of the patient-reported concerns and their relevance with demographics and clinical characteristics.\n\nThe participants will be given tasks to complete 6 tools survey before, during, and after radiotherapy.",[86,87,88,89,90,41,91,25],"Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Squamous Cell Carcinoma","Oropharynx Cancer","Nasopharyngeal Cancer","Tongue Cancer",[78,86,93,94,95],"Radiotherapy","COSMIN","Cancer","2024-10-26",{"date":98,"type":63},"2024-10-29",{"date":100,"type":63},"2023-05-01",{"date":102,"type":21},"2025-10-01",{"name":104,"class":105},"King Saud University","OTHER",1]